PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes

PolTREG S.A. announced it received a Notice of Allowance from the United States Patent and Trademark Office, covering the manufacturing of T-regulatory cells to treat Type-1 Diabetes, and ways the therapy is administered.

Scroll to Top